Terminated PHASE3 INTERVENTIONAL 2-arm NCT00616902

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 (PRIMO II)

Clinical Study Protocol M10-221 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

Sponsor: Abbott

Conditions Chronic Kidney Disease (CKD) Stage 5 Hypertrophy, Left Ventricular

Interventions Placebo Injection 4 mcg/mL paricalcitol injection 4 mcg/mL

Updated 8 times since 2017 Last updated: Jan 18, 2012 Started: Jan 31, 2009 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was prematurely terminated due to low enrollment

Other terminated trials from Abbott

See all terminations from Abbott

This PHASE3 trial investigates Chronic Kidney Disease (CKD) Stage 5 and Hypertrophy, Left Ventricular and is currently terminated or withdrawn. Abbott leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Harvard University
Massachusetts General Hospital

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arvada, United States , Athens, Greece , Atlanta, United States , Bakersfield, United States , Bologna, Italy , Brno, Czechia , Brooklyn, United States , Bucharest, Romania , Caguas, Puerto Rico , Chicago, United States and 56 more locations